title: [Winuron - alternative single-dose therapy of gonorrhea].
abstract: 152 ambulatory patients suffering from gonorrhoea were treated with Winuron in an open clinical trial. A single oral dose of rosoxacin 300 mg proved to be sufficient to cure 97.4% of the patients. Follow-up examination revealed only 4 cases of Neisseria gonorrhoea left. Already 3 days after therapy, the clinical symptoms had subsided in 84.1% of the patients. The substance was well-tolerated. Side effects were observed in 14.5% of the cases, being mild and transitory, though. Good and antibacterial efficacy of rosoxacin in vitro as well as the high healing quotient in combination with the shortest possible duration of therapy make Winuron a valuable alternative to penicillin.
mesh_terms: D042462:4-Quinolones; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D015363:Quinolones
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin
vernacular_title: Winuron - Alternative Einmaltherapie der Gonorrhoe.